These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38978570)

  • 1. Pilot study of humanized glypican-3-targeted zirconium-89 immuno-positron emission tomography for hepatocellular carcinoma.
    Dickerson LK; Lehnert AL; Hamlin DK; Labadie KP; Goodsell KE; Liu Y; Li Y; Wilbur DS; Miyaoka R; Park JO
    Res Sq; 2024 Jun; ():. PubMed ID: 38978570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma.
    Sham JG; Kievit FM; Grierson JR; Chiarelli PA; Miyaoka RS; Zhang M; Yeung RS; Minoshima S; Park JO
    J Nucl Med; 2014 Dec; 55(12):2032-7. PubMed ID: 25359880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma.
    Sham JG; Kievit FM; Grierson JR; Miyaoka RS; Yeh MM; Zhang M; Yeung RS; Minoshima S; Park JO
    J Nucl Med; 2014 May; 55(5):799-804. PubMed ID: 24627434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glypican-3 targeted positron emission tomography detects sub-centimeter tumors in a xenograft model of hepatocellular carcinoma.
    Labadie KP; Lehnert AL; Kenoyer AL; Hamlin DK; Ludwig AD; Utria AF; Daniel SK; Mihailovic TN; Prossnitz A; Orozco JJ; Li Y; Wilbur DS; Miyaoka RS; Park JO
    EJNMMI Res; 2023 Apr; 13(1):35. PubMed ID: 37103671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Humanized Anti-GPC3 Antibody for Immuno-Positron Emission Tomography Imaging of Orthotopic Mouse Model of Patient-Derived Hepatocellular Carcinoma Xenografts.
    Natarajan A; Zhang H; Ye W; Huttad L; Tan M; Chua MS; Gambhir SS; So SK
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glypican-3 targeted delivery of
    Labadie KP; Ludwig AD; Lehnert AL; Hamlin DK; Kenoyer AL; Sullivan KM; Daniel SK; Mihailovic TN; Sham JG; Orozco JJ; Yeung RS; Chen DL; Wilbur DS; Miyaoka RS; Park JO
    Sci Rep; 2021 Feb; 11(1):3731. PubMed ID: 33580090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GPC3-targeted immunoPET imaging of hepatocellular carcinomas.
    An S; Zhang D; Zhang Y; Wang C; Shi L; Wei W; Huang G; Liu J
    Eur J Nucl Med Mol Imaging; 2022 Jul; 49(8):2682-2692. PubMed ID: 35147737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glypican-3-Targeted
    Labadie KP; Hamlin DK; Kenoyer A; Daniel SK; Utria AF; Ludwig AD; Kenerson HL; Li L; Sham JG; Chen DL; Orozco JJ; Yeung RS; Orvig C; Li Y; Wilbur DS; Park JO
    J Nucl Med; 2022 Jul; 63(7):1033-1038. PubMed ID: 34772791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Site-Specifically Conjugated Single-Domain Antibody Successfully Identifies Glypican-3-Expressing Liver Cancer by Immuno-PET.
    Fayn S; King AP; Gutsche NT; Duan Z; Buffington J; Olkowski CP; Fu Y; Hong J; Sail D; Baidoo KE; Swenson RE; Cheloha RW; Ho M; Choyke PL; Escorcia FE
    J Nucl Med; 2023 Jul; 64(7):1017-1023. PubMed ID: 36997331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging of hepatocellular carcinoma patient-derived xenografts using ⁸⁹Zr-labeled anti-glypican-3 monoclonal antibody.
    Yang X; Liu H; Sun CK; Natarajan A; Hu X; Wang X; Allegretta M; Guttmann RD; Gambhir SS; Chua MS; Cheng Z; So SK
    Biomaterials; 2014 Aug; 35(25):6964-71. PubMed ID: 24836949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiofluorinated GPC3-Binding Peptides for PET Imaging of Hepatocellular Carcinoma.
    Li Y; Zhang J; Gu J; Hu K; Huang S; Conti PS; Wu H; Chen K
    Mol Imaging Biol; 2020 Feb; 22(1):134-143. PubMed ID: 31044341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical PET imaging of bispecific antibody ERY974 targeting CD3 and glypican 3 reveals that tumor uptake correlates to T cell infiltrate.
    Waaijer SJ; Giesen D; Ishiguro T; Sano Y; Sugaya N; Schröder CP; de Vries EG; Lub-de Hooge MN
    J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32217763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Imaging the expression of glypican-3 in hepatocellular carcinoma by PET.
    Wang Z; Han YJ; Huang S; Wang M; Zhou WL; Li HS; Wang QS; Wu HB
    Amino Acids; 2018 Feb; 50(2):309-320. PubMed ID: 29204748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma.
    Lin F; Clift R; Ehara T; Yanagida H; Horton S; Noncovich A; Guest M; Kim D; Salvador K; Richardson S; Miller T; Han G; Bhat A; Song K; Li G
    J Nucl Med; 2024 Apr; 65(4):586-592. PubMed ID: 38423788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glypican-3 deficiency in liver cancer upregulates MAPK/ERK pathway but decreases cell proliferation.
    Chung JY; Lee W; Lee OW; Ylaya K; Nambiar D; Sheehan-Klenk J; Fayn S; Hewitt SM; Choyke PL; Escorcia FE
    Am J Cancer Res; 2024; 14(7):3348-3371. PubMed ID: 39113871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The development of a Glypican-3-specific binding peptide using
    Qin Y; Cheng S; Li Y; Zou S; Chen M; Zhu D; Gao S; Wu H; Zhu L; Zhu X
    Biomater Sci; 2020 Oct; 8(20):5656-5665. PubMed ID: 32896851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Yttrium-90-Labeled Anti-Glypican 3 Radioimmunotherapy Halts Tumor Growth in an Orthotopic Xenograft Model of Hepatocellular Carcinoma.
    Ludwig AD; Labadie KP; Seo YD; Hamlin DK; Nguyen HM; Mahadev VM; Yeung RS; Wilbur DS; Park JO
    J Oncol; 2019; 2019():4564707. PubMed ID: 31636665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 89Zr-ImmunoPET Shows Therapeutic Efficacy of Anti-CD20-IFNα Fusion Protein in a Murine B-cell Lymphoma Model.
    Zettlitz KA; Salazar FB; Yamada RE; Trinh KR; Vasuthasawat A; Timmerman JM; Morrison SL; Wu AM
    Mol Cancer Ther; 2022 Apr; 21(4):607-615. PubMed ID: 35086952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD146-targeted immunoPET and NIRF Imaging of Hepatocellular Carcinoma with a Dual-Labeled Monoclonal Antibody.
    Hernandez R; Sun H; England CG; Valdovinos HF; Ehlerding EB; Barnhart TE; Yang Y; Cai W
    Theranostics; 2016; 6(11):1918-33. PubMed ID: 27570560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and
    Ma XH; Wang S; Liu SY; Chen K; Wu ZY; Li DF; Mi YT; Hu LB; Chen ZW; Zhao XM
    World J Gastroenterol; 2019 Jun; 25(24):3030-3043. PubMed ID: 31293339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.